Repurposing the Veterinary Antiprotozoal Drug Ronidazole for the Treatment of Clostridioides difficile Infection
- 9 October 2020
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 56 (6) , 106188
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 17 references indexed in Scilit:
- Colonization Resistance of the Gut Microbiota against Clostridium difficileAntibiotics, 2015
- Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile InfectionCanadian Journal of Infectious Diseases and Medical Microbiology, 2015
- Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant StaphylococciThe Journal of Antibiotics, 2014
- Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidenceInternational Journal of Antimicrobial Agents, 2012
- Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults.2012
- Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin ProductionJournal of Bacteriology, 2010
- A Mouse Model of Clostridium difficile–Associated DiseaseGastroenterology, 2008
- Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococciJournal of Antimicrobial Chemotherapy, 2004
- [Research on Pharmachim's ronidazole for its antifertility, embryotoxic and teratogenic action].1985
- Ronidazole in Low Concentrations in Drinking Water for Treatment and Development of Immunity to Swine DysenteryAmerican Journal of Veterinary Research, 1976